Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors
1 1-41-3222 13a 1-33 3-63-85-71 2 24The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Calkyl, Cfluoroalkyl or -(CH)OH; Ris a hydrogen atom (H), methyl or Cfluoroalkyl; Ris a hydrogen atom (H) or Calkyl; Ris optionally substituted branched Calkyl, optionally substitut...
Saved in:
| Main Authors | , , , , , , , , , , , |
|---|---|
| Format | Patent |
| Language | English |
| Published |
05.05.2009
|
| Online Access | Get full text |
Cover
Loading…
| Abstract | 1 1-41-3222 13a 1-33 3-63-85-71 2 24The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Calkyl, Cfluoroalkyl or -(CH)OH; Ris a hydrogen atom (H), methyl or Cfluoroalkyl; Ris a hydrogen atom (H) or Calkyl; Ris optionally substituted branched Calkyl, optionally substituted Ccycloalkyl, optionally substituted mono-unsaturated-Ccycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which nand nindependently are 1 or 2; and Y is O, S, SO, or NR; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis. |
|---|---|
| AbstractList | 1 1-41-3222 13a 1-33 3-63-85-71 2 24The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Calkyl, Cfluoroalkyl or -(CH)OH; Ris a hydrogen atom (H), methyl or Cfluoroalkyl; Ris a hydrogen atom (H) or Calkyl; Ris optionally substituted branched Calkyl, optionally substituted Ccycloalkyl, optionally substituted mono-unsaturated-Ccycloalkenyl, optionally substituted phenyl, or an optionally substituted heterocyclic group of sub-formula (aa), (bb) or (cc): in which nand nindependently are 1 or 2; and Y is O, S, SO, or NR; and wherein Het is of sub-formula (i), (ii), (iii), (iv) or (v): The compounds are phosphodiesterase (PDE) inhibitors, in particular PDE4 inhibitors. Also provided is the use of a compound of formula (I), or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment and/or prophylaxis of an inflammatory and/or allergic disease in a mammal such as a human, for example chronic obstructive pulmonary disease (COPD), asthma, or allergic rhinitis. |
| Author | Hamblin, Julie Nicole Cooper, Anthony William James Lindvall, Mika Kristian Mitchell, Charlotte Jane Johnson, Martin Redpath Redgrave, Alison Judith Dowle, Michael Dennis Edlin, Christopher David Cook, Caroline Mary Allen, David George Coe, Diane Mary Jones, Paul Spencer |
| Author_xml | – sequence: 1 givenname: David George surname: Allen fullname: Allen, David George – sequence: 2 givenname: Diane Mary surname: Coe fullname: Coe, Diane Mary – sequence: 3 givenname: Caroline Mary surname: Cook fullname: Cook, Caroline Mary – sequence: 4 givenname: Anthony William James surname: Cooper fullname: Cooper, Anthony William James – sequence: 5 givenname: Michael Dennis surname: Dowle fullname: Dowle, Michael Dennis – sequence: 6 givenname: Christopher David surname: Edlin fullname: Edlin, Christopher David – sequence: 7 givenname: Julie Nicole surname: Hamblin fullname: Hamblin, Julie Nicole – sequence: 8 givenname: Martin Redpath surname: Johnson fullname: Johnson, Martin Redpath – sequence: 9 givenname: Paul Spencer surname: Jones fullname: Jones, Paul Spencer – sequence: 10 givenname: Mika Kristian surname: Lindvall fullname: Lindvall, Mika Kristian – sequence: 11 givenname: Charlotte Jane surname: Mitchell fullname: Mitchell, Charlotte Jane – sequence: 12 givenname: Alison Judith surname: Redgrave fullname: Redgrave, Alison Judith |
| BookMark | eNqNijsKwkAQQLfQwt8d5gAJqImYWlEsU9iJyOiOZiDOLDubIp5eBQ9g8XjweGM3EBUaubruI7601VORlfnmHPrInoXgps-gnXjLAMVDaogjdEaABqFR--CZLFHET2Rp-MpJo03d8I6t0ezniYP97rg95J0FTCTJLo-IX83Xq2W1KKvij-UNeaQ6IA |
| ContentType | Patent |
| CorporateAuthor | Glaxo Group Limited |
| CorporateAuthor_xml | – name: Glaxo Group Limited |
| DBID | EFH |
| DatabaseName | USPTO Issued Patents |
| DatabaseTitleList | |
| Database_xml | – sequence: 1 dbid: EFH name: USPTO Issued Patents url: http://www.uspto.gov/patft/index.html sourceTypes: Open Access Repository |
| DeliveryMethod | fulltext_linktorsrc |
| ExternalDocumentID | 07528148 |
| GroupedDBID | EFH |
| ID | FETCH-uspatents_grants_075281483 |
| IEDL.DBID | EFH |
| IngestDate | Sun Mar 05 22:31:10 EST 2023 |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | false |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-uspatents_grants_075281483 |
| OpenAccessLink | https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7528148 |
| ParticipantIDs | uspatents_grants_07528148 |
| PatentNumber | 7528148 |
| PublicationCentury | 2000 |
| PublicationDate | 20090505 |
| PublicationDateYYYYMMDD | 2009-05-05 |
| PublicationDate_xml | – month: 05 year: 2009 text: 20090505 day: 05 |
| PublicationDecade | 2000 |
| PublicationYear | 2009 |
| References | (WO-02/098878) 20021200 Hoehn et al. (3833594) 19740900 Montana et al., Annual Reports in Medicinal Chemistry, 2001, vol. 36, pp. 41-56. Ochiai H. et al.; New orally active PDE4 inhibitors with therapeutic potential; Bioorg. Med. Chem.; 2004 (stated to have been available online Jun. 20, 2004); 12(15); pp. 4089-4100. Yu G., Mason H.J., et. al.; Substituted pyrazolopyridines as potent and selective PDE5 inhibitors: potential agents for treatment of erectile disfunction; Journal of Medicinal Chemistry; 2001; 44; pp. 1025-1027. Ochiai H. et al.; Bioorg. Med. Chem. Web Release; 2003. De Mello, A. Echevarria, et al.; Antileishmanial Pyrazolopyridine Derivatives: Synthesis and Structure-Activity Relationship Analysis; Journal of Medicinal Chemistry; 2004; 47(22); pp. 5427-5432. (WO-03/016563) 20030200 Dow et al. (5593997) 19970100 Chemical Abstracts Registry-CAS registry No. 502143-17-1 which has the laboratory code NSC 235755, Apr. 8, 2003. Hohn H et al: Potential Antidiabetic Agents. Pyrazolo63,4-b!pyridinesW Journal of Medicinal Chemistry, American Chemical Society. Washington, US, vol. 16, No. 12, 1973, pp. 1340-1346, XP002097814 ISSN: 0022-2623 p. 1343; compound 37. U.S. Appl. No. 10/598,838, filed Mar. 2005, Christensen, IV. Giembycz M.A.; Phosphodiesterase 4 Inhibitors and the Treatment of Asthma: Where Are We Now and Where Do We Go from Here?; Drugs; 2000; 59(2); pp. 193-212. Denzel et al. (3833598) 19740900 Hoehn et al. (3979399) 19760900 Patel J.B. and Malick J.B.; Pharmacological properties of tracazolate: a new non-benzodiazepine anxiolytic agent; Eur. J. Pharmacol.; 1982; 78; pp. 323-333. U.S. Appl. No. 10/598,973, filed Mar. 2005, Cook, et al. Shi D., et al.; Pyrazolopyridines: effect of structural alterations on activity at adenosine- and GABA-A receptors; Drug Development Research; 1997; 42; pp. 41-56. Patel J.B., et al.; "Pharmacology of pyrazolopyridines"; Pharmacology Biochemistry & Behaviour; 1985; vol. 23; pp. 675-680. Ochiai H. et al.; Discovery of new orally active phosphodiesterase (PDE4) inhibitors; Chem. Pharm. Bull.; 2004 (stated to have been published online Jun. 15, 2004); 52(9); pp 1098-1104. Daly J. W. et al.; 1-methyl-4-substituted-1H-pyrazolo [3,4-b] pyridine-5-carboxylic acid derivatives: effect of structural alterations on activity at A1 and A2 adenosine receptors; Medicinal Chemistry Research; 1994; 4(5); pp. 293-306; Birkhaeuser; Boston US. Glass II, W. F., et al.; "Inhibition of human lung cyclic GMP and cyclic AMP phosphodiesterases by certain nucleosides, nucleotides, and pharmacological phosphodiesterase inhibitors"; Biochemical Pharmacology; 1979; 28; pp. 1107-1112. Sabitha, et al.; A Facile Route to Pyrazolo[3,4-b]Pyridines and [1]Benzopyrano[4′,3′-e]Pyrazolo[3,4-b]Pyridines; Indian Institute of Chemical Technology; 1999; 29(4),655-665; Synthetic Communications; India. Hoehn et al. (3856799) 19741200 Hoehn et al. (3755340) 19730800 Allen et al. (2006/0089375) 20060400 (0 180 318) 19860500 Hoen et al. (3840546) 19741000 (WO-01/44244) 20010600 Davis A., et al.,; "Strategic approaches to drug design. II. Modelling studies on phosphodiesterase substrates and inhibitors"; Journal of Computer-Aided Molecular Design; 1987; 1; pp. 97-119. Schweighoffer et al. (2005/0043319) 20050200 (WO-2005/090353) 20050900 (WO-2005/058892) 20050600 Hoehn et al. (4115394) 19780900 Denzel TH.; (translation of title: New Synthesis of 1-Unsubstituted 1H-Pyrazolo [3.4-b] Pyridine-5-Carboxylic Acid Esters); Archiv der Pharmazie; 1974; 307(3); pp. 177-186. Ochiai H. et al.; New orally active PDE4 inhibitors with therapeutic poteintial; Bioorg. Med. Chem. Lett.; Jan. 5, 2004 issue (available as "articles in press" version on or before Dec. 4, 2003, possibly Oct. 2003, via internet); 14(1); pp. 29-32. Bondavalli F. et al; Synthesis, molecular modelling studies, and pharmacological activity of selective A1 receptor antagonists; Journal of Medicinal Chemistry; 2002; 45(22); pp. 4875-4887. Hoehn et al. (3925388) 19751200 Hoehn H. et al.; 1H-pyrazolo[3,4-b]pyridines; Journal of Heterocyclic Chemistry; 1972; 9(2); pp. 235-253. (WO-02/060900) 20020800 (151 1006) 19750400 Hoehn et al. (3966746) 19760600 (WO-2004/024728) 20040300 Beer B., et al.; "Enhancement of 3H-diazepam binding by SQ 65,396: a novel anti-anxiety agent"; Pharmacology Biochemistry & Behaviour; 1978; 9; pp. 849-851. (1003419) 19770100 Kripalani K. J. et al.; "Biotransformation in the monkey of cartazolate (SQ 65,396), a substituted pyrazolopyridine having anxiolytic activity"; Xenobiotica; 1981; 11(7); pp. 481-488. (WO-02/081463) 20021000 Chakravorti; Synthesis of Some Isoquinolylpyrazolo[3,4-b]pyridine Derivatives as Possible Antifilarial Agents; Indian J. Chem.; Feb. 1978; vol. 16B, pp. 161-163. (WO-2005/090348) 20050900 Chasin M., et al.; "1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)-a potent new inhibitor of cyclic 3′,5′-nucleotide phosphodiesterases"; Biochemical Pharmacology; 1972; 21; pp. 2443-2450. Bare T.M. et al.; Synthesis and structure-activity relationships of a series of anxioselective pyrazolopyridine ester and amide anxiolytic agents; Journal of Medicinal Chemistry; 1989; 32; pp. 2561-2573. (WO 00/15222) 20000300 (WO-2004/056823) 20040700 Allen et al. (2006/0252790) 20061100 Schenone S. et al.; Synthesis and biological data of 4-amino-1-(2-chloro-2-phenylethyl)-1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid ethyl esters, a new series of A1-adenosine receptor (A1AR) ligands; Bioorg. Med. Chem. Lett.; 2001; 11; pp. 2529-2531. (141 7489) 19731200 (553 799) 19740900 (WO-01/23389) 20010400 Polson J. B., et al.; "Analysis of the relationship between pharmacological inhibition of cyclic nucleotide phosphodiesterase and relaxation of canine tracheal smooth muscle"; Biochemical Pharmacology; 1979; 28; pp. 1391-1395 RBI 1998, Catalogue No. T-112, Tracazolate; 1998; p. 340. Weinryb I., et al.; "Studies in vitro and in vivo with SQ-20,009: an inhibitor of cyclic nucleoside phosphodiesterase with central nervous system activity"; Excerpta Med. Int. Congr. Ser.; 1975; 359; pp. 857-865. Allen et al. (2007/0111995) 20070500 Horowitz Z. P., et al.; "Cyclic AMP and anxiety"; Psychosomatics; 1972; vol. XIII, No. 2; pp. 85-92. (0 076 035) 19830400 (WO-00/15222) 20000300 (2002-020386) 20020100 (WO-2005/090354) 20050900 |
| References_xml | – year: 19740900 ident: 3833598 contributor: fullname: Denzel et al. – year: 19730800 ident: 3755340 contributor: fullname: Hoehn et al. – year: 20040300 ident: WO-2004/024728 – year: 19970100 ident: 5593997 contributor: fullname: Dow et al. – year: 20000300 ident: WO-00/15222 – year: 19830400 ident: 0 076 035 – year: 20050900 ident: WO-2005/090354 – year: 19770100 ident: 1003419 – year: 19740900 ident: 553 799 – year: 19760600 ident: 3966746 contributor: fullname: Hoehn et al. – year: 20050600 ident: WO-2005/058892 – year: 19860500 ident: 0 180 318 – year: 20020800 ident: WO-02/060900 – year: 20010400 ident: WO-01/23389 – year: 19750400 ident: 151 1006 – year: 19731200 ident: 141 7489 – year: 19741000 ident: 3840546 contributor: fullname: Hoen et al. – year: 20050900 ident: WO-2005/090353 – year: 20070500 ident: 2007/0111995 contributor: fullname: Allen et al. – year: 20040700 ident: WO-2004/056823 – year: 20010600 ident: WO-01/44244 – year: 20020100 ident: 2002-020386 – year: 19780900 ident: 4115394 contributor: fullname: Hoehn et al. – year: 19741200 ident: 3856799 contributor: fullname: Hoehn et al. – year: 19751200 ident: 3925388 contributor: fullname: Hoehn et al. – year: 19760900 ident: 3979399 contributor: fullname: Hoehn et al. – year: 20000300 ident: WO 00/15222 – year: 20021200 ident: WO-02/098878 – year: 20050900 ident: WO-2005/090348 – year: 20030200 ident: WO-03/016563 – year: 19740900 ident: 3833594 contributor: fullname: Hoehn et al. – year: 20060400 ident: 2006/0089375 contributor: fullname: Allen et al. – year: 20021000 ident: WO-02/081463 – year: 20061100 ident: 2006/0252790 contributor: fullname: Allen et al. – year: 20050200 ident: 2005/0043319 contributor: fullname: Schweighoffer et al. |
| Score | 2.7259912 |
| Snippet | 1 1-41-3222 13a 1-33 3-63-85-71 2 24The invention relates to a compound of formula (I) or a salt thereof: wherein: Ris Calkyl, Cfluoroalkyl or -(CH)OH; Ris a... |
| SourceID | uspatents |
| SourceType | Open Access Repository |
| Title | Pyrazolo[3,4-B]pyridine compounds, and their use as phosphodiesterase inhibitors |
| URI | https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7528148 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEB52F0E9KSquL3LwuNF2kz5yVbYUD9KDwoLI0rSpW9C0NC2y_nonrSxeFJLLBJJhQmYyyZcvANcK_T6GcUalwEyHF8qn0pvnVGSFDBVTgsue7fPRj5_5w9JbjiDevoX5wGVEa9TF3HSmbqseXInufZh4OpA_W45AbdkHPvV7leZJXtwG3jzErf0YxqFjoV2LKN6HXewCt2y6Nb-CRnQAO0kvPYSR0keQJJsm_UJf88JmnN691pumxMChiEV128-NzIxgWk_6o3vSGUVSQ-p1ZbBaqJ99KozCUq9LWdo_co6BRIun-5huh1-9NRbWsnJ-1GQnMMH0Xp0C8YQsAlcI6asMzcbTgKssdLPczVieMmcK0z-7Ofun7Rz2hpsPD8sFTNqmU5cYQFt51VvnG5dwfXU |
| link.rule.ids | 230,309,786,808,891,64396 |
| linkProvider | USPTO |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8QwEB7WVXycFBXXZw4eN7rdpK-ruqU-WHpQWBApTZvuFrQtTYusv95JK4sXheQygcmQx3wzyWQCcClR7yOMMypc9HR4Ki0qzHFC3TgVjmTS5aLN9jm1_Bf-MDNnPfBXb2E-cBvREmVRV40q66INrkT13k087ZI_6xyBuc4-8Jm_F1ESJOm1bY4dNO3XYF1jrF7rE8_fgS1kgkZbXqtfsOHtwkbQUvegJ_N9CIJlFX2htnllQ05v3spllSF0SKLjuvX3RmpI0LEn7eE9aZQkkSLlolBYdbCffiyMxCxfZCLTv-QcAPEmz7c-XXUfzisd2BKOfgRlh9BHB18eATFdkdqG6wpLxjhwPLK5jB0jToyYJREbDWDwJ5vjf9ouYDO488Kn--njCWx31yAmllPo11UjzxBNa3HeDtQ35oGAcQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=Pyrazolo%5B3%2C4-B%5Dpyridine+compounds%2C+and+their+use+as+phosphodiesterase+inhibitors&rft.inventor=Allen%2C+David+George&rft.inventor=Coe%2C+Diane+Mary&rft.inventor=Cook%2C+Caroline+Mary&rft.inventor=Cooper%2C+Anthony+William+James&rft.inventor=Dowle%2C+Michael+Dennis&rft.inventor=Edlin%2C+Christopher+David&rft.inventor=Hamblin%2C+Julie+Nicole&rft.inventor=Johnson%2C+Martin+Redpath&rft.inventor=Jones%2C+Paul+Spencer&rft.inventor=Lindvall%2C+Mika+Kristian&rft.inventor=Mitchell%2C+Charlotte+Jane&rft.inventor=Redgrave%2C+Alison+Judith&rft.number=7528148&rft.date=2009-05-05&rft.externalDBID=n%2Fa&rft.externalDocID=07528148 |